-
Join 357 other subscribers
Blogroll
HIV/AIDS networks
Links
- bilaterals.org
- Fix the Patent Laws!
- FTA Malaysia
- HAI Europe
- Health Action International (HAI)
- Intellectual Property Watch
- Lawyers Collective HIV/AIDS
- MSF Access Campaign
- Patent Opposition Database
- Public Citizen
- Stop EU-India FTA
- Stop Peru FTA
- Third World Network
- Treatment Action Group
- UAEM Europe
- UAEM evidence collection
- Universities Allied for Essential Medicines (UAEM)
Archives
-
Recent Posts
- Clamour against United Kingdom’s free-trade negotiator
- India, EU conclude another round of talks for proposed trade agreement
- Next round of India, UK talks for free trade agreement to be held in March
- ‘Playing with the lives of HIV patients’: Drug shortages force many to change medication regime
- Pfizer’s Covid pill Paxlovid gets WHO’s approval. All you need to know
Categories
Category Archives: India
India’s antimicrobial resistance and how to solve this problem
Powerful medications are slowly becoming ineffective for many Indians due to misuse of antibiotics Source: FreePressJournal A recent ICMR report has left healthcare providers, patients, and infection control experts worried about the rising Antimicrobial Resistance in India. The report says … Continue reading
Posted in Access to Medicins, Antibiotics, COVID-19, Diseases/Therapies, Drugs, Generics, India, Quality, Vaccines
Tagged COVID19, Generics, India, Medicine, Medicines, therapeutics
Leave a comment
Antimicrobial resistance is rising in India, says ICMR report.
Source: TheTimes Of India MUMBAI: More than 50% of the ICU patients battling a type of the Pneumonia caused by bacteria Klebsiella Pneumoniae will not respond to powerful antibiotics called carbapenem. Another antibiotics, imipenem, will not affect a mutated form of … Continue reading
Posted in Access to Medecines, Access to Medicins, Antibiotics, COVID-19, Diseases/Therapies, Drugs, Generics, India, Vaccines
Tagged COVID19, Generics, India, Medicine, therapeutics
Leave a comment
Merck and Singapore sign deal on COVID-19 antiviral pill
Source: Reuters SINGAPORE, Oct 6 (Reuters) – Pharmaceutical company Merck announced on Wednesday a supply and purchase agreement with Singapore that will ensure it access to its experimental oral COVID-19 antiviral drug, the latest Asian country aiming to get supplies. … Continue reading
Posted in Access to Medecines, Access to Medicins, COVID-19, Diseases/Therapies, Generics, India
Tagged COVID19, Generics, India, Medicine, therapeutics
Leave a comment
MERCK SELLS FEDERALLY FINANCED COVID PILL TO U.S. FOR 40 TIMES WHAT IT COSTS TO MAKE
Source: TheIntercept The Covid-19 treatment molnupiravir was developed using funding from the National Institutes of Health and the Department of Defense. A FIVE-DAY COURSE of molnupiravir, the new medicine being hailed as a “huge advance” in the treatment of Covid-19, costs … Continue reading
Merck’s molnupiravir will be a blockbuster drug during pandemic. What about endemic COVID-19?
Source: FiercePharma After showing a 50% reduction in the risk of hospitalization or death, Merck & Co. and Ridgeback Biotherapeutics’ molnupiravir looks on track to secure an FDA emergency use authorization and become a blockbuster earner during the pandemic. But what … Continue reading
Posted in Access to Medecines, Access to Medicins, COVID-19, Diseases/Therapies, Drug prices, Drugs, Generics, India, Uncategorized
Tagged COVID19, Generics, India, Medicine, therapeutics
Leave a comment
Explained | Molnupiravir, Merck’s new drug to treat COVID-19
Source: The Hindu Data shows drug halves chances of hospitalisation in patients with mild to moderate disease. Pharmaceutical major Merck and Ridgeback Biotherapeutics announced via a press release on October 1 the early results from Phase-3 trials that its anti-viral … Continue reading
Posted in COVID-19, Drug prices, Drugs, Generics, India, Uncategorized
Tagged Access to Medicines Index, COVID19, India, Medicine, therapeutics
Leave a comment
“Indian CSO letter to the DPIIT on the proposed amendment to the Patent Rules”
20th May, 2019 New Delhi 16 May 2019 To Shri Ramesh Abhishek Secretary, Department for Promotion of Industry and Internal Trade, Ministry of Commerce & Industry, Room No.157 Udyog Bhawan, New Delhi Telephone : 2306 1815, 2306 1667, 23061598(F) … Continue reading
The Cost of Cancer: WHO Report Says Expensive Drugs ‘Impairing’ Access to Cure
Source: NEWS18 1st Feb 2019, New Delhi A recent report by the World Health Organisation (WHO) says the standard treatment for breast cancer can drain 10 years of average annual income in India. Forty-five-year old Virendra Sharma’s father was diagnosed … Continue reading
Posted in Access to Medecines, Cancer, Drug prices, India, Patent
Leave a comment
RCEP and affordable medicines: Civil society reaches out to Minister of Commerce Suresh Prabhu
12th Nov 2018, New Delhi The RCEP ministerial meeting is taking place today, 12th November, 2018 in Singapore. It will be followed by Leaders’ Summit on 14th November. There are clear indications that countries want to wrap up the negotiations that started in … Continue reading
People living with hepatitis C and HIV challenge evergreening patents on lifesaving hepatitis C drugs in India
New Delhi, 10 July 2018: Delhi Network of Positive People (DNP+) has filed today two patent oppositions before the Indian patent office, challenging additional patent claims by US pharmaceutical corporation-Gilead Sciences for the hepatitis C medicines sofosbuvir and velpatasvir. These … Continue reading
Posted in Drug prices, Hepatitis C, Indian Patent Law, Patent, Patent Opposition, Sec 3 (d)
Tagged DNP+, Gilead Sciences
Leave a comment
Don't trade our lives away 